New study finds the consequences of post-tuberculosis adds substantially to the disease burden caused by tuberculosis.

Stop TB Partnership highlights devastating and continued impact of COVID-19 pandemic on children affected by TB.

Children infected with cytomegalovirus—a type of common herpes virus—before they were 12 months old were more than three times as likely to develop tuberculosis disease in their childhood than babies who did not contract the virus in their first year.

In order to increase the knowledge base for normative guidance on optimal treatment modalities for drug-resistant tuberculosis (DR-TB), WHO is announcing a publicly accessible global individual patient data (IPD) platform for drug-resistant tuberculosis treatment (DR-TB-IPD). This will be a secure but accessible platform containing outcomes of over 10,000 drug-resistant TB patients as the starting point and expanding this with data received in response to a recent public call for data.

A team of United States-based scientists recently conducted a study to evaluate the effect of Mycobacterium tuberculosis infection on the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Treatment with an updated fixed-dose combination (FDC) of rifampicin/isoniazid/ pyrazinamide may decrease the risk for insufficient exposure to rifampicin among children with tuberculosis (TB) infection, according to results of a prospective study published in Clinical Infectious Diseases.

Treatment Action Group releases a patent landscape investigating potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines.

Tuberculosis preventive therapy is highly effective in preventing TB disease and death, yet only a few people have access to it. Tiyese Jeranji reports in Spotlight on how Médecins Sans Frontières in Khayelitsha (Cape Town, South Africa) is helping TB patients and their contacts access preventive therapy in the comfort of their homes as part of a new family-centred care initiative.

Global Fund Board approves new strategy placing people and communities at center to lead fight against HIV, TB, malaria, to build systems for health, equity and strengthen pandemic preparedness

10 November 2021: The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB). This is the first TB regimen based on preclinical evidence of effectiveness that is less than four-months long to be studied in a clinical trial. A5362 will evaluate the potential efficacy of clofazimine when combined with treatments that have been proven to be effective against TB.